Man Group plc Sells 18,921 Shares of DaVita Inc. (NYSE:DVA)

Man Group plc decreased its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 64.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,260 shares of the company's stock after selling 18,921 shares during the period. Man Group plc's holdings in DaVita were worth $1,534,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Occudo Quantitative Strategies LP bought a new position in shares of DaVita in the 4th quarter worth approximately $290,000. NDVR Inc. raised its position in shares of DaVita by 28.9% in the 4th quarter. NDVR Inc. now owns 1,714 shares of the company's stock worth $256,000 after acquiring an additional 384 shares in the last quarter. Lighthouse Investment Partners LLC bought a new position in shares of DaVita in the 4th quarter worth approximately $1,645,000. Iron Triangle Partners LP bought a new position in shares of DaVita in the 4th quarter worth approximately $38,946,000. Finally, Jefferies Financial Group Inc. raised its position in shares of DaVita by 28.6% in the 4th quarter. Jefferies Financial Group Inc. now owns 174,880 shares of the company's stock worth $26,153,000 after acquiring an additional 38,855 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

DaVita Stock Up 1.2%

Shares of DaVita stock traded up $1.63 during midday trading on Tuesday, hitting $139.82. The company had a trading volume of 794,960 shares, compared to its average volume of 826,146. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock has a market capitalization of $10.56 billion, a P/E ratio of 13.02, a P/E/G ratio of 1.07 and a beta of 1.14. The company has a 50 day moving average of $145.09 and a 200 day moving average of $153.34. DaVita Inc. has a 52-week low of $131.76 and a 52-week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The firm had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter in the previous year, the business earned $2.26 earnings per share. The company's revenue was up 5.0% on a year-over-year basis. On average, equities analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DVA. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Barclays increased their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. Truist Financial cut their price target on DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research note on Monday, May 19th. Finally, Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $164.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.